Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma

Marcello Tiseo, Olga Martelli, Andrea Mancuso, Maria Pia Sormani, Paolo Bruzzi, Roberto Di Salvia, Filippo De Marinis, Andrea Ardizzoni

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Aims and background: Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also several toxic effects. In particular, the major dose-limiting effect appears to be renal toxicity. In several countries, to reduce nephrotoxicity after cisplatin administration, a 24-h hydration is recommended following a chemotherapy treatment in a hospital regimen. In our institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment. Methods and study design: To assess incidence of cisplatin nephrotoxicity using a short hydration regimen, which included 2000 ml of fluids with control of diuresis, individual outpatient data was pooled retrospectively from patients enrolled in large randomized studies regarding cisplatin-based chemotherapy in lung cancer and mesothelioma. From February 1999 to November 2002, 107 patients treated with cisplatin (≥75 mg/m2/cycle) were examined, monitoring serum creatinine and creatinine clearance levels. Results: Five patients out of 107 (4.6%) were withdrawn from chemotherapy because of renal toxicity. For the other 102 patients, serum creatinine and creatinine clearance measurements were stable around the normal values during treatment. No time trends relating to serum creatinine levels or creatinine clearance and cycle numbers or cisplatin-cumulative doses were detected (P = 0.36 and P = 0.64, for the relationship with cycle number, and P = 0.39 and P = 0.65 for the relationship with cumulative dose, respectively, random effect model) after adjusting for the total number of cycles administered. Conclusions: These observations indicate that intermediate to high-dose cisplatin administration is feasible in outpatient management with a short hydration regimen without high risk of nephrotoxicity.

Original languageEnglish
Pages (from-to)138-144
Number of pages7
JournalTumori
Volume93
Issue number2
Publication statusPublished - Mar 2007

Fingerprint

Mesothelioma
Cisplatin
Lung Neoplasms
Outpatients
Drug Therapy
Creatinine
Diuresis
Therapeutics
Serum
Kidney
Poisons
Furosemide
Combination Drug Therapy
Neoplasms
Reference Values
Incidence

Keywords

  • Cisplatin
  • Hydration
  • Nephrotoxicity
  • Outpatient regimen

ASJC Scopus subject areas

  • Cancer Research

Cite this

Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. / Tiseo, Marcello; Martelli, Olga; Mancuso, Andrea; Sormani, Maria Pia; Bruzzi, Paolo; Di Salvia, Roberto; De Marinis, Filippo; Ardizzoni, Andrea.

In: Tumori, Vol. 93, No. 2, 03.2007, p. 138-144.

Research output: Contribution to journalArticle

Tiseo, Marcello ; Martelli, Olga ; Mancuso, Andrea ; Sormani, Maria Pia ; Bruzzi, Paolo ; Di Salvia, Roberto ; De Marinis, Filippo ; Ardizzoni, Andrea. / Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. In: Tumori. 2007 ; Vol. 93, No. 2. pp. 138-144.
@article{c0d3bfc0814940e490c24377a245a199,
title = "Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma",
abstract = "Aims and background: Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also several toxic effects. In particular, the major dose-limiting effect appears to be renal toxicity. In several countries, to reduce nephrotoxicity after cisplatin administration, a 24-h hydration is recommended following a chemotherapy treatment in a hospital regimen. In our institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment. Methods and study design: To assess incidence of cisplatin nephrotoxicity using a short hydration regimen, which included 2000 ml of fluids with control of diuresis, individual outpatient data was pooled retrospectively from patients enrolled in large randomized studies regarding cisplatin-based chemotherapy in lung cancer and mesothelioma. From February 1999 to November 2002, 107 patients treated with cisplatin (≥75 mg/m2/cycle) were examined, monitoring serum creatinine and creatinine clearance levels. Results: Five patients out of 107 (4.6{\%}) were withdrawn from chemotherapy because of renal toxicity. For the other 102 patients, serum creatinine and creatinine clearance measurements were stable around the normal values during treatment. No time trends relating to serum creatinine levels or creatinine clearance and cycle numbers or cisplatin-cumulative doses were detected (P = 0.36 and P = 0.64, for the relationship with cycle number, and P = 0.39 and P = 0.65 for the relationship with cumulative dose, respectively, random effect model) after adjusting for the total number of cycles administered. Conclusions: These observations indicate that intermediate to high-dose cisplatin administration is feasible in outpatient management with a short hydration regimen without high risk of nephrotoxicity.",
keywords = "Cisplatin, Hydration, Nephrotoxicity, Outpatient regimen",
author = "Marcello Tiseo and Olga Martelli and Andrea Mancuso and Sormani, {Maria Pia} and Paolo Bruzzi and {Di Salvia}, Roberto and {De Marinis}, Filippo and Andrea Ardizzoni",
year = "2007",
month = "3",
language = "English",
volume = "93",
pages = "138--144",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma

AU - Tiseo, Marcello

AU - Martelli, Olga

AU - Mancuso, Andrea

AU - Sormani, Maria Pia

AU - Bruzzi, Paolo

AU - Di Salvia, Roberto

AU - De Marinis, Filippo

AU - Ardizzoni, Andrea

PY - 2007/3

Y1 - 2007/3

N2 - Aims and background: Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also several toxic effects. In particular, the major dose-limiting effect appears to be renal toxicity. In several countries, to reduce nephrotoxicity after cisplatin administration, a 24-h hydration is recommended following a chemotherapy treatment in a hospital regimen. In our institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment. Methods and study design: To assess incidence of cisplatin nephrotoxicity using a short hydration regimen, which included 2000 ml of fluids with control of diuresis, individual outpatient data was pooled retrospectively from patients enrolled in large randomized studies regarding cisplatin-based chemotherapy in lung cancer and mesothelioma. From February 1999 to November 2002, 107 patients treated with cisplatin (≥75 mg/m2/cycle) were examined, monitoring serum creatinine and creatinine clearance levels. Results: Five patients out of 107 (4.6%) were withdrawn from chemotherapy because of renal toxicity. For the other 102 patients, serum creatinine and creatinine clearance measurements were stable around the normal values during treatment. No time trends relating to serum creatinine levels or creatinine clearance and cycle numbers or cisplatin-cumulative doses were detected (P = 0.36 and P = 0.64, for the relationship with cycle number, and P = 0.39 and P = 0.65 for the relationship with cumulative dose, respectively, random effect model) after adjusting for the total number of cycles administered. Conclusions: These observations indicate that intermediate to high-dose cisplatin administration is feasible in outpatient management with a short hydration regimen without high risk of nephrotoxicity.

AB - Aims and background: Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also several toxic effects. In particular, the major dose-limiting effect appears to be renal toxicity. In several countries, to reduce nephrotoxicity after cisplatin administration, a 24-h hydration is recommended following a chemotherapy treatment in a hospital regimen. In our institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment. Methods and study design: To assess incidence of cisplatin nephrotoxicity using a short hydration regimen, which included 2000 ml of fluids with control of diuresis, individual outpatient data was pooled retrospectively from patients enrolled in large randomized studies regarding cisplatin-based chemotherapy in lung cancer and mesothelioma. From February 1999 to November 2002, 107 patients treated with cisplatin (≥75 mg/m2/cycle) were examined, monitoring serum creatinine and creatinine clearance levels. Results: Five patients out of 107 (4.6%) were withdrawn from chemotherapy because of renal toxicity. For the other 102 patients, serum creatinine and creatinine clearance measurements were stable around the normal values during treatment. No time trends relating to serum creatinine levels or creatinine clearance and cycle numbers or cisplatin-cumulative doses were detected (P = 0.36 and P = 0.64, for the relationship with cycle number, and P = 0.39 and P = 0.65 for the relationship with cumulative dose, respectively, random effect model) after adjusting for the total number of cycles administered. Conclusions: These observations indicate that intermediate to high-dose cisplatin administration is feasible in outpatient management with a short hydration regimen without high risk of nephrotoxicity.

KW - Cisplatin

KW - Hydration

KW - Nephrotoxicity

KW - Outpatient regimen

UR - http://www.scopus.com/inward/record.url?scp=34249870118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249870118&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 138

EP - 144

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -